Skip to content

MDMA research published in 2009

75 studies whose primary subject is MDMA were published in 2009, down from 80 in 2008. Newest first. Back to the MDMA overview

Studies

Effects of the endogenous PPAR‐α agonist, oleoylethanolamide on MDMA‐induced cognitive deficits in mice

Synapse December 22, 2009 Ainhoa Plaza‐zabala, Fernando Berrendero, Juan Suárez et al. 3 citations

Abstract MDMA (3,4‐Methylenedioxymethamphetamine) is an amphetamine derivative widely used for recreational purposes. We have recently shown that repeated treatment with high doses of MDMA‐induced impairments in the acquisition and recall of an active avoidance task in mice. In this study, we examined whether the endogenous peroxisome proliferator‐activated receptor‐α (PPAR‐α) agonist,...

DOI: 10.1002/syn.20733 (opens in new tab) MDMA Agonist Pars compacta Dopamine transporter +6

Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).

Toxicology and Applied Pharmacology December 15, 2009 Julien Fonsart, Marie-Claude Menet, Marcel Debray et al.

The use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) has increased in recent years; it can lead to life-threatening hyperthermia and serotonin syndrome. Human and rodent males appear to be more sensitive to acute toxicity than are females. MDMA is metabolized to five main metabolites by the enzymes CYP1A2, CYP2D and COMT. Little is presently known about sex-dependent differences in the...

Effects of chronic intracerebroventricular 3,4-methylenedioxy-N-methamphetamine (MDMA) or fluoxetine on the active avoidance test in rats with or without exposure to mild chronic stress.

Behavioural Brain Research December 14, 2009 Laura A León, Jesus Landeira-Fernandez, Fernando P. Cárdenas

In despite the similarity of mechanisms of action between both selective serotonin reuptake inhibitors (SSRI) and MDMA (main compound of "Ecstasy") there are relatively few reports on the effects of the later on animal models of depression. There are many animal models designed to create or to assess depression. Mild chronic stress (MCS) is a procedure designed to create depression. MCS...

MDMA (ecstasy) modulates locomotor and prefrontal cortex sensory evoked activity.

Brain Research December 11, 2009 Kristal D. Atkins, Tilithia Burks, Alan C. Swann et al.

Ingestion of 3, 4-methylenedioxymethamphetamine (MDMA) leads to heightened response to sensory stimulation; thus, MDMA is referred to as "ecstasy" because it produces pleasurable enhancement of such sensation. There have been no electrophysiological studies that report the consequences of MDMA on sensory input. The present study was initiated to study the effects of acute and chronic MDMA on...

Dopamine transporter down-regulation following repeated cocaine: implications for 3,4-methylenedioxymethamphetamine-induced acute effects and long-term neurotoxicity in mice.

British Journal of Pharmacology December 10, 2009 Inés Peraile, Elisa Torres, Andrea Mayado et al.

Background and purpose: 3,4-Methylenedioxymethamphetamine (MDMA) and cocaine are two widely abused psychostimulant drugs targeting the dopamine transporter (DAT). DAT availability regulates dopamine neurotransmission and uptake of MDMA-derived neurotoxic metabolites. We aimed to determine the effect of cocaine pre-exposure on the acute and long-term effects of MDMA in mice. Experimental...

Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats.

Behavioural Pharmacology December 2009 Katharine A Brennan, Caleb Carati, Rod A Lea et al.

It has been suggested that activation of dopamine D1-like and D2-like receptors contribute equally to the maintenance of drug self-administration. This study compared the contribution of these receptor subtypes to 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine (MA) self-administration. Effects of pretreatment with the D2-like receptor antagonist, eticlopride (0.0, 0.0125, 0.025 or...

Cannabis and Ecstasy/MDMA: Empirical Measures of Creativity in Recreational Users

Journal of Psychoactive Drugs December 1, 2009 Katy A. Jones, Mark Blagrove, A. C. Parrott 41 citations

This study investigated the associations between chronic cannabis and Ecstasy/MDMA use and one objective and two subjective measure of creativity. Fifteen abstinent Ecstasy users, 15 abstinent cannabis users, and 15 nondrug-user controls, completed three measures of creativity: the Consequences behavioral test of creativity, self-assessed performance on the Consequences test, and Gough's Trait...

Effects of 3,4‐methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity

Journal of Neurochemistry November 30, 2009 Dominik K. Biezonski, Jerrold S. Meyer 47 citations

J. Neurochem. (2009) 112 , 951–962. Abstract 3,4‐Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) is a popular recreational drug used worldwide. This study aimed to determine the effects of this compound on the expression of nerve terminal serotonergic markers in rats. Experiment 1 investigated MDMA‐induced changes in levels of the serotonin transporter (SERT) and the vesicular monoamine...

Harms associated with psychoactive substances: findings of the UK National Drug Survey

Journal of Psychopharmacology November 25, 2009 Celia J. A. Morgan, Leslie Muetzelfeldt, Mark Muetzelfeldt et al. 80 citations

Nutt and colleagues' 'rational' scale to assess the harms of commonly used drugs was based on ratings by a panel of experts. This survey aimed to assess drug users' views of the harms of drugs using the same scale. As users' drug choices are not solely based on harms, we additionally assessed perceived benefits. The survey was hosted at http://www.nationaldrugsurvey.org. UK residents reported...

Role of Serotonin via 5-HT2B Receptors in the Reinforcing Effects of MDMA in Mice

PLoS One November 20, 2009 Stéphane Doly, Jesus Bertran‐gonzalez, Jacques Callebert et al. 80 citations

The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) reverses dopamine and serotonin transporters to produce efflux of dopamine and serotonin, respectively, in regions of the brain that have been implicated in reward. However, the role of serotonin/dopamine interactions in the behavioral effects of MDMA remains unclear. We previously showed that MDMA-induced locomotion,...

A fatal case of myocardial damage due to misuse of the "designer drug" MDMA.

Legal medicine (Tokyo, Japan) November 2009 Rie Sano, Toshikazu Hasuike, Minoru Nakano et al.

A 39-year-old woman collapsed after oral intake of 3,4-methylenedioxymethyl-amphetamine (MDMA, "ecstasy"). After ingestion of the drug, she had felt persistent discomfort in her anterior chest area, and lost consciousness for a few minutes on the following morning. She was transported to a hospital and died seven days after collapse. A serum sample obtained on admission revealed an MDMA...

Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.

Drug Metabolism and Disposition November 2009 Michael H. Baumann, Dorota Zolkowska, Insook Kim et al.

Based on animal data, there is speculation that (+ or -)-3,4-methylenedioxymethamphetamine (MDMA) is neurotoxic to humans. Extrapolation of MDMA findings from animals to humans requires assessment of pharmacokinetics in various species, and low-dose administration data from rats are lacking. In this study, we examine MDMA pharmacokinetics in rats given low (2 mg/kg) and high (10 mg/kg) doses of...

Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study.

Sleep November 2009 Surilla Randall, Chris‐ellyn Johanson, Manuel E. Tancer et al.

3,4-Methylenedioxymethamphetamine (MDMA) affects monoamine neurotransmitters that play a critical role in sleep and daytime alertness. However, the acute effects of MDMA on sleep and daytime sleepiness have not been studied under placebo-controlled conditions. This study was designed to establish the effects of acute MDMA or placebo administration and sleep restriction on sleep and daytime...

Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.

Journal of Pharmacology and Experimental Therapeutics November 1, 2009 Kevin S. Murnane, Naoki Murai, Leonard L. Howell et al. 34 citations

3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse "ecstasy." The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in other species. MDMA shares biological effects with both amphetamine-type stimulants and mescaline-type hallucinogens, which may be attributable to distinct effects of its two...

Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.

Brain Research October 6, 2009 Gloria M P Roberts, Liam Nestor, Hugh P Garavan

It has been consistently shown that ecstasy users display impairments in learning and memory performance. In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI). Using functional imaging and a face-learning task, we investigated neural...

Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neurotoxicity.

Drug Metabolism and Disposition October 2009 Melanie Mueller, Jie Yuan, Anne Felim et al.

The mechanism by which the recreational drug (+/-)-3,4-methylenedioxymethamphetamine (MDMA) destroys brain serotonin (5-HT) axon terminals is not understood. Recent studies have implicated MDMA metabolites, but their precise role remains unclear. To further evaluate the relative importance of metabolites versus the parent compound in neurotoxicity, we explored the relationship between...

MDMA pretreatment leads to mild chronic unpredictable stress-induced impairments in spatial learning.

Behavioral Neuroscience October 1, 2009 Jacobi I. Cunningham, Jamie Raudensky, John Tonkiss et al. 27 citations

3,4-Methylenedioxymethamphetamine (MDMA) is a drug of abuse worldwide and a selective serotonin (5-HT) neurotoxin. An important factor in the risk of drug abuse and relapse is stress. Although multiple parallels exist between MDMA abuse and stress, including effects on 5-HTergic neurotransmission, few studies have investigated the consequences of combined exposure to MDMA and chronic stress....

DOI: 10.1037/a0016716 (opens in new tab) MDMA Serotonergic Serotonin transporter Hippocampus +3

Enzymatic–nonenzymatic cellular antioxidant defense systems response and immunohistochemical detection of MDMA, VMAT2, HSP70, and apoptosis as biomarkers for MDMA (Ecstasy) neurotoxicity

Journal of Neuroscience Research October 1, 2009 Irene Riezzo, Daniela Cerretani, Carmela Fiore et al. 47 citations

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA)‐induced neurotoxicity leads to the formation of quinone metabolities and hydroxyl radicals and then to the production of reactive oxygen species (ROS). We evaluated the effect of a single dose of MDMA (20 mg/kg, i.p.) on the enzymatic and nonenzymatic cellular antioxidant defense system in different areas of rat brain in the early hours (<6 hr)...